Advocacy intelligence hub — real-time data for patient organizations
Gustave Roussy, Cancer Campus, Grand Paris — NA
Josh Peterson — NA
Vasileios Kalles — NA
First Affiliated Hospital of Zhejiang University — PHASE2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Emory University — NA
Centre Hospitalier Universitaire de la Réunion — NA
NRG Oncology — PHASE3
University of Miami Sylvester Comprehensive Cancer Center — NA
M.D. Anderson Cancer Center — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Herceptin
(trastuzumab)Orphan drugstandardGenentech, Inc.
HER2/neu Receptor Antagonist [EPC]
12.1 Mechanism of Action The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to th...
Enhertu
(fam-trastuzumab deruxtecan-nxki)Orphan drugstandardDaiichi Sankyo, Inc.
12.1 Mechanism of Action Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The s...
Aromasin
(Exemestane)Orphan drugstandardPharmacia & Upjohn
Aromatase Inhibitor [EPC]
12.1 Mechanism of Action Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens b...
Tukysa
(tucatinib)Orphan drugstandardSeagen Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in...
Giovanni Corso, MD
European Institute of Oncology
Michael Goggins, MD, MB BCh BAO
Johns Hopkins University
📍 PHILADELPHIA, PA
Xiaosong Chen
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
Niloy J Samadder
Mayo Clinic
📍 SCOTTSDALE, AZ
Inge I.R. Konings, MD PhD
Amsterdam UMC
Vincent V.O. Dezentjé, MD PhD
NKI-AvL